Quick Answer
Centessa Pharmaceuticals plc reported Diluted EPS of $1.46 per share (loss) for fiscal year 2025.
Centessa Pharmaceuticals plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.46 | +29.1% |
| 2024 | -$2.06 | -31.2% |
| 2023 | -$1.57 | +32.0% |
| 2022 | -$2.31 | +54.4% |
| 2021 | -$5.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.41 | -10.8% | -7.9% |
| June 30, 2025 | -$0.38 | +5.0% | -90.0% |
| March 31, 2025 | -$0.20 | +47.4% | +45.9% |
| September 30, 2024 | -$0.37 | +7.5% | +7.5% |
| June 30, 2024 | -$0.40 | -53.8% | -5.3% |
| March 31, 2024 | -$0.38 | +28.3% | +5.0% |
| September 30, 2023 | -$0.40 | +29.8% | -53.8% |
| June 30, 2023 | -$0.26 | +62.3% | +50.9% |
- Centessa Pharmaceuticals plc showed an increase of +29.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Centessa Pharmaceuticals plc’s diluted eps has grown by 71.2% (from $5.07 per share (loss) to $1.46 per share (loss)).
- The most recent figure is from Centessa Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: